Maurine D'Agostino1, Nicolas Tesse2, Rose Anne Lavergne3, Patrice Le Pape3, Jean Philippe Bouchara4, Jean Pol Frippiat5, Marie Machouart6, Anne Debourgogne6. 1. Université de Lorraine, SIMPA, F-54000 Nancy, France. Electronic address: maurine.d-agostino@univ-lorraine.fr. 2. Société Septeos, 12 avenue de la grande armée, 75017 Paris, France. 3. Laboratoire de Parasitologie-Mycologie, Institut de Biologie, CHU de Nantes, France, and Département de Parasitologie et Mycologie Médicale, Université de Nantes, Nantes Atlantique Universités, EA1155-IICiMed, Faculté de Pharmacie, Nantes, France. 4. Host-Pathogen Interaction Study Group (GEIHP, EA 3142), SFR ICAT 4208, Univ. Angers, Univ. Brest, Angers University Hospital, Angers, France. 5. Université de Lorraine, SIMPA, F-54000 Nancy, France. 6. Université de Lorraine, SIMPA, F-54000 Nancy, France; Université de Lorraine, CHRU-Nancy, Laboratoire de Microbiologie, F-54000 Nancy, France.
Abstract
OBJECTIVES: Today, the increase of invasive fungal infections and the emergence of resistant strains are observed in medical practice. New antifungals are expected, and the plant world offers a panel of potentially active molecules. CIN-102 is a mixture of seven different compounds of plant origin developed from the formulation of cinnamon essential oil. METHODS: The in vitro activity of CIN-102 was characterised against Aspergillus spp., Fusarium spp. and Scedosporium spp. by studying the minimum inhibitory concentration (MIC), inoculum effect, germination inhibition, fungal growth, post-antifungal effect (PAFE) and synergy. RESULTS: MICs determined for the three genera followed a unimodal distribution and their mean values ranged from 62-250 μg/mL. CIN-102 demonstrated an inoculum effect similar to voriconazole and amphotericin B, 100% inhibition of spore germination and a PAFE. CONCLUSION: CIN-102 has significant activity against filamentous fungi involved in human pathologies and should be further explored as a potential new treatment. Other studies regarding its mechanisms of action as well as animal investigations are awaited.
OBJECTIVES: Today, the increase of invasive fungal infections and the emergence of resistant strains are observed in medical practice. New antifungals are expected, and the plant world offers a panel of potentially active molecules. CIN-102 is a mixture of seven different compounds of plant origin developed from the formulation of cinnamon essential oil. METHODS: The in vitro activity of CIN-102 was characterised against Aspergillus spp., Fusarium spp. and Scedosporium spp. by studying the minimum inhibitory concentration (MIC), inoculum effect, germination inhibition, fungal growth, post-antifungal effect (PAFE) and synergy. RESULTS: MICs determined for the three genera followed a unimodal distribution and their mean values ranged from 62-250 μg/mL. CIN-102 demonstrated an inoculum effect similar to voriconazole and amphotericin B, 100% inhibition of spore germination and a PAFE. CONCLUSION:CIN-102 has significant activity against filamentous fungi involved in human pathologies and should be further explored as a potential new treatment. Other studies regarding its mechanisms of action as well as animal investigations are awaited.
Authors: Maurine D'agostino; Nicolas Tesse; Rose Anne Lavergne; Patrice Le Pape; Jean Pol Frippiat; Marie Machouart; Anne Debourgogne Journal: J Med Microbiol Date: 2021-09 Impact factor: 2.472